Acadia Pharmaceuticals

SAN DIEGO, CA · CIK 0001070494 · Biotech · Public

Small-molecule pharmaceuticals for neurological disorders and rare diseases

acadiapharm.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$107M
2 Form D · Jan 2013
165 months since last filing
Contracts
—
No federal contracts on record
Patents
40
19 granted · 21 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$21,069,109
Private capital raisedForm D · SEC$86,385,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2818Relation Therapeutics—$116M
2819STEL Technologies, LLC——
2820Passage Bio—$110M
2821Acadia Pharmaceuticals—$107M
2822Neurogene Inc.—$106M
2823Ovid Therapeutics—$106M
2824LEAP THERAPEUTICS, INC.—$105M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • THOMAS AASENExecutive Officer
  • GLENN BAITYExecutive Officer
  • MICHAEL BORERDirector
  • LAURA BREGEDirector
  • MARY ANN GRAYDirector
  • ULI HACKSELLDirector · Executive Officer
  • LESLIE IVERSENDirector
  • LESTER KAPLANDirector
  • ROGER MILLSExecutive Officer
  • TORSTEN RASMUSSENDirector
  • WILLIAM WELLSDirector

Patents

USPTO · 19 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.